First-line PARP inhibition in ovarian cancer — standard of care for all?

被引：0
|
作者：
Susana N. Banerjee
Christopher J. Lord
机构：
[1] The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
[2] Breast Cancer Now Toby Robins Research Centre and Cancer Research UK Gene Function Laboratory,undefined
[3] Institute of Cancer Research,undefined
来源：
Nature Reviews Clinical Oncology | 2020年 / 17卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In 2018, the SOLO1 trial set a new standard of care with maintenance olaparib substantially extending progression-free survival (PFS) in women with newly-diagnosed BRCA1/2-mutated advanced-stage ovarian cancer. Herein, we summarize trials of first-line poly(ADP-ribose) polymerase (PARP) inhibition beyond BRCA1/2 mutations, including combination strategies, and discuss the optimum use of PARP inhibition in advanced-stage ovarian cancer.
引用
收藏
页码：136 / 137
页数：1
相关论文
共 50 条
  • [1] First-line PARP inhibition in ovarian cancer - standard of care for all?
    Banerjee, Susana N.
    Lord, Christopher J.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (03) : 136 - 137
  • [2] First-line bevacizumab for ovarian cancer—new standard of care?
    Susana Banerjee
    Stan B. Kaye
    [J]. Nature Reviews Clinical Oncology, 2012, 9 : 194 - 196
  • [3] GYNECOLOGICAL CANCER First-line bevacizumab for ovarian cancer-new standard of care?
    Banerjee, Susana
    Kaye, Stan B.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (04) : 194 - 196
  • [4] PARP inhibitors in first-line of ovarian cancers
    Rodrigues, Manuel
    [J]. BULLETIN DU CANCER, 2020, 107 (01) : 4 - 5
  • [5] PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
    Franzese, Elisena
    Diana, Anna
    Centonze, Sara
    Pignata, Sandro
    De Vita, Ferdinando
    Ciardiello, Fortunato
    Orditura, Michele
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [6] Olaparib maintenance for first-line treatment of ovarian cancer:will SOLO1 reset the standard of care?
    Miller, Rowan E.
    Crusz, Shanthini M.
    Ledermann, Jonathan A.
    [J]. FUTURE ONCOLOGY, 2019, 15 (16) : 1845 - 1853
  • [7] The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
    Bookman, M. A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 211 - 217
  • [8] Treatment Considerations for PARP Inhibitors in First-Line Maintenance Therapy in Patients With Advanced Ovarian Cancer
    Previs, Rebecca
    [J]. ONCOLOGY-NEW YORK, 2021, 35 (04): : 224 - 227
  • [9] Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients
    Yuan, Hua
    Li, Ning
    Wu, Lingying
    Yao, Hongwen
    [J]. JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
  • [10] Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients
    Hua Yuan
    Ning Li
    Lingying Wu
    Hongwen Yao
    [J]. Journal of Ovarian Research, 17
12345